{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:56:58Z","timestamp":1790758618489,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03043-7","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:04:26Z","timestamp":1790755466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of prolonged hypogonadism in men with prolactinomas despite biochemical remission: the role of baseline luteinizing hormone"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-811X","authenticated-orcid":false,"given":"Gokberk","family":"Gozukan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-5356","authenticated-orcid":false,"given":"Busra","family":"Tunc Topuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7684-0319","authenticated-orcid":false,"given":"Ceren","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-5704","authenticated-orcid":false,"given":"Emre Sedar","family":"Saygili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-2656","authenticated-orcid":false,"given":"Ersen","family":"Karakilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"12","key":"3043_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"3043_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/bs.vh.2024.11.001","volume":"129","author":"Y Rudman","year":"2025","unstructured":"Rudman Y, Shimon I (2025) Hypogonadism in men with prolactinoma: diagnosis, treatment, and management of persistent hypogonadism. Vitam Horm 129:185\u2013202. https:\/\/doi.org\/10.1016\/bs.vh.2024.11.001","journal-title":"Vitam Horm"},{"issue":"4","key":"3043_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","volume":"25","author":"KM Al Dahmani","year":"2022","unstructured":"Al Dahmani KM, Almalki MH, Ekhzaimy A, Aziz F, Bashier A, Mahzari MM et al (2022) Proportion and predictors of hypogonadism recovery in men with macroprolactinomas treated with dopamine agonists. Pituitary 25(4):658\u2013666. https:\/\/doi.org\/10.1007\/s11102-022-01242-y","journal-title":"Pituitary"},{"issue":"6","key":"3043_CR4","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","volume":"25","author":"Y Rudman","year":"2022","unstructured":"Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I (2022) Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25(6):882\u2013890. https:\/\/doi.org\/10.1007\/s11102-022-01259-3","journal-title":"Pituitary"},{"issue":"3","key":"3043_CR5","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12020-025-04433-2","volume":"90","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li Y, Cui Q, Zheng H, Sun W, Chen L, Zhu X, Li Y, Ye H, Zhang S, Liu X, Ji L (2025) Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists. Endocrine 90(3):1438\u20131445. https:\/\/doi.org\/10.1007\/s12020-025-04433-2","journal-title":"Endocrine"},{"key":"3043_CR6","doi-asserted-by":"publisher","first-page":"1338345","DOI":"10.3389\/fendo.2024.1338345","volume":"15","author":"L Dzialach","year":"2024","unstructured":"Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P (2024) Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. Front Endocrinol (Lausanne) 15:1338345. https:\/\/doi.org\/10.3389\/fendo.2024.1338345","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"3043_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","volume":"27","author":"SM Constantinescu","year":"2024","unstructured":"Constantinescu SM, Maiter D, Alexopoulou O (2024) Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists. Pituitary 27(5):625\u2013634. https:\/\/doi.org\/10.1007\/s11102-024-01445-5","journal-title":"Pituitary"},{"issue":"12","key":"3043_CR8","doi-asserted-by":"publisher","first-page":"dgaa650","DOI":"10.1210\/clinem\/dgaa650","volume":"105","author":"M Sehemby","year":"2020","unstructured":"Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK et al (2020) Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. J Clin Endocrinol Metab 105(12):dgaa650. https:\/\/doi.org\/10.1210\/clinem\/dgaa650","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3043_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11102-025-01548-7","volume":"28","author":"A Milioto","year":"2025","unstructured":"Milioto A, Petolicchio C, Mattioli L, Campana C, Arecco A, Ferone D, Cocchiara F, Gatto F (2025) Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia. Pituitary 28(4):75. https:\/\/doi.org\/10.1007\/s11102-025-01548-7","journal-title":"Pituitary"},{"issue":"1","key":"3043_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S, Acromegaly Consensus Group (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"5","key":"3043_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715\u20131744. https:\/\/doi.org\/10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"3043_CR12","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al (2016) Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101(11):3888\u20133921. https:\/\/doi.org\/10.1210\/jc.2016-2118","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3043_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/cen.12124","volume":"79","author":"N Karavitaki","year":"2013","unstructured":"Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JAH (2013) Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf) 79(2):217\u2013223. https:\/\/doi.org\/10.1111\/cen.12124","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"3043_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12020-025-04215-w","volume":"89","author":"Y Rudman","year":"2025","unstructured":"Rudman Y, Simon N, Shimon R, Drozdinsky G, Markus E, Duskin-Bitan H et al (2025) Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study. Endocrine 89(1):212\u2013221. https:\/\/doi.org\/10.1007\/s12020-025-04215-w","journal-title":"Endocrine"},{"issue":"10","key":"3043_CR15","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1172\/JCI63937","volume":"122","author":"C Sonigo","year":"2012","unstructured":"Sonigo C, Bouilly J, Carr\u00e9 N, Tolle V, Caraty A, Tello J et al (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest 122(10):3791\u20133795. https:\/\/doi.org\/10.1172\/JCI63937","journal-title":"J Clin Invest"},{"issue":"3","key":"3043_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","volume":"17","author":"I Shimon","year":"2014","unstructured":"Shimon I, Benbassat C (2014) Male prolactinomas presenting with normal testosterone levels. Pituitary 17(3):246\u2013250. https:\/\/doi.org\/10.1007\/s11102-013-0497-x","journal-title":"Pituitary"},{"issue":"6","key":"3043_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40618-025-02559-8","volume":"48","author":"M Detomas","year":"2025","unstructured":"Detomas M, Altieri B, Nasi-Kordhishti I, Ryba A, Haberbosch L, Chierigo F et al (2025) Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study. J Endocrinol Invest 48(6):1363\u20131370. https:\/\/doi.org\/10.1007\/s40618-025-02559-8","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"3043_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.25179\/tjem.2020-77688","volume":"24","author":"G Simsek Bagir","year":"2020","unstructured":"Simsek Bagir G, Gunesli A, Eksi Haydardedeoglu F, Bakiner OS, Alkan O, Ertorer ME (2020) Knosp and Hardy grading systems are useful in predicting persistence of male hypogonadism in prolactinomas following prolactin normalization. Turk J Endocrinol Metab 24(4):284\u2013292. https:\/\/doi.org\/10.25179\/tjem.2020-77688","journal-title":"Turk J Endocrinol Metab"},{"issue":"1","key":"3043_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh A, Benbassat C, Lifshitz A, Shimon I (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18(1):108\u2013115. https:\/\/doi.org\/10.1007\/s11102-014-0563-z","journal-title":"Pituitary"},{"key":"3043_CR20","doi-asserted-by":"publisher","first-page":"1705300","DOI":"10.3389\/fendo.2025.1705300","volume":"16","author":"A Prinzi","year":"2025","unstructured":"Prinzi A, Fava G, Bacchi I, Spitali F, Galvano A, Arnaldi G, Frasca F, Guarnotta V, Malandrino P (2025) Pituitary hormone deficiencies in prolactinomas: prevalence, predictors, and functional recovery. Front Endocrinol (Lausanne) 16:1705300. https:\/\/doi.org\/10.3389\/fendo.2025.1705300","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3043_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/cen.14633","volume":"96","author":"CN Jayasena","year":"2022","unstructured":"Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S et al (2022) Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf) 96(2):200\u2013219. https:\/\/doi.org\/10.1111\/cen.14633","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"3043_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1210\/jcem-64-2-391","volume":"64","author":"JC Prior","year":"1987","unstructured":"Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64(2):391\u2013394. https:\/\/doi.org\/10.1210\/jcem-64-2-391","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3043_CR23","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-21-0977","volume":"186","author":"R Cozzi","year":"2022","unstructured":"Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M et al (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol 186(3):P1\u2013P33. https:\/\/doi.org\/10.1530\/EJE-21-0977","journal-title":"Eur J Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03043-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03043-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03043-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:04:27Z","timestamp":1790755467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-03043-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":23,"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03043-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"4 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Canakkale Onsekiz Mart University Non-Interventional Clinical Research Ethics Committee (approval no. 2026-73; approval date: 25 March 2026) and was conducted in accordance with the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective design of the study, the requirement for informed consent was waived by the ethics committee.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}